|
Back to Home » June 2020 News » Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis |
Subcutaneous Daratumumab Combination Resulted in Deep and Rapid Hematologic Responses and Improved Clinical Outcomes in the Treatment of Patients with Newly Diagnosed Light Chain (AL) Amyloidosis |
June 13, 2020
RARITAN, N.J., June 13, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumabi in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a...
Source URL: https://www.prnewswire.com:443/news-releases/subcutaneous-daratumumab-combination-resulted-in-deep-and-rapid-hematologic-responses-and-improved-clinical-outcomes-in-the-treatment-of-patients-with-newly-diagnosed-light-chain-al-amyloidosis-301075337.html
|
|
|
|
